Dimensional Fund Advisors LP boosted its position in shares of Regenxbio Inc (NASDAQ:RGNX) by 157.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 321,713 shares of the biotechnology company’s stock after buying an additional 196,944 shares during the period. Dimensional Fund Advisors LP owned approximately 0.90% of Regenxbio worth $13,496,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in RGNX. NumerixS Investment Technologies Inc bought a new stake in shares of Regenxbio in the 4th quarter valued at approximately $50,000. Riverhead Capital Management LLC lifted its stake in shares of Regenxbio by 137.5% in the 3rd quarter. Riverhead Capital Management LLC now owns 1,900 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 1,100 shares during the last quarter. LS Investment Advisors LLC lifted its stake in shares of Regenxbio by 63.1% in the 4th quarter. LS Investment Advisors LLC now owns 2,260 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 874 shares during the last quarter. Meeder Asset Management Inc. lifted its stake in shares of Regenxbio by 31.7% in the 4th quarter. Meeder Asset Management Inc. now owns 2,578 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 621 shares during the last quarter. Finally, Pacer Advisors Inc. bought a new stake in shares of Regenxbio in the 3rd quarter valued at approximately $227,000. 82.18% of the stock is owned by institutional investors.
Several research firms have recently issued reports on RGNX. BidaskClub lowered Regenxbio from a “hold” rating to a “sell” rating in a research note on Tuesday. ValuEngine raised Regenxbio from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 5th. Evercore ISI raised Regenxbio from an “in-line” rating to an “outperform” rating and set a $51.25 price objective for the company in a research note on Monday, February 25th. Zacks Investment Research lowered Regenxbio from a “buy” rating to a “hold” rating in a research note on Saturday, February 23rd. Finally, Raymond James raised Regenxbio from an “outperform” rating to a “strong-buy” rating and set a $94.00 price objective for the company in a research note on Tuesday, February 5th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, four have issued a buy rating and two have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $77.97.
Shares of RGNX stock opened at $54.65 on Friday. Regenxbio Inc has a 52-week low of $35.65 and a 52-week high of $85.10. The company has a debt-to-equity ratio of 0.01, a current ratio of 15.24 and a quick ratio of 15.24. The company has a market cap of $2.00 billion, a P/E ratio of 22.96 and a beta of 0.47.
Regenxbio (NASDAQ:RGNX) last issued its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.43. Regenxbio had a return on equity of 22.33% and a net margin of 45.74%. Research analysts expect that Regenxbio Inc will post -3.22 EPS for the current year.
WARNING: This story was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/4303947/dimensional-fund-advisors-lp-increases-position-in-regenxbio-inc-rgnx.html.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
See Also: Is the QQQ ETF safe?
Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regenxbio Inc (NASDAQ:RGNX).
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.